SEC Form SC 13G filed by Gamida Cell Ltd.

2/8/24 8:25:28 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $GMDA alert in real time by email

SC 13G 1 GMDA022024.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.)* GAMIDA CELL LTD. ------------------------------------------------------ (NAME OF ISSUER) Ordinary shares, par value NIS 0.01 per share ------------------------------------------------------ (TITLE OF CLASS OF SECURITIES) M47364100 ------------------------------------------------------ (CUSIP NUMBER) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the notes. - ------------------------------------------------------------------------------ 1 NAME OF REPORTING PERSONS S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Levin Capital Strategies, L.P. (EIN 87-0753486) - ------------------------------------------------------------------------------ - ------------------------------------------------------------------------------ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [ ] - ------------------------------------------------------------------------------ - ------------------------------------------------------------------------------ 3 SEC USE ONLY - ------------------------------------------------------------------------------ - ------------------------------------------------------------------------------ 4 CITIZENSHIP OR PLACE OF ORGANIZATION United States of America - ------------------------------------------------------------------------------ - ------------------------------------------------------------------------------ 5 SOLE VOTING POWER 0 NUMBER OF --------------------------------------------------------------- --------------------------------------------------------------- SHARES 6 SHARED VOTING POWER BENEFICIALLY OWNED BY 8,749,996 --------------------------------------------------------------- --------------------------------------------------------------- EACH 7 SOLE DISPOSITIVE POWER REPORTING PERSON 0 --------------------------------------------------------------- --------------------------------------------------------------- WITH 8 SHARED DISPOSITIVE POWER 8,749,996 - ------------------------------------------------------------------------------ - ------------------------------------------------------------------------------ 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9,128,376 - ------------------------------------------------------------------------------ - ------------------------------------------------------------------------------ 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* [ ] - ------------------------------------------------------------------------------ - ------------------------------------------------------------------------------ 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 6.9% - ------------------------------------------------------------------------------ - ------------------------------------------------------------------------------ 12 TYPE OF REPORTING PERSON* IA - ------------------------------------------------------------------------------ - ------------------------------------------------------------------------------ 1 NAME OF REPORTING PERSONS S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Levin Capital Strategies GP, LLC (EIN 87-0753486) - ------------------------------------------------------------------------------ - ------------------------------------------------------------------------------ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [ ] - ------------------------------------------------------------------------------ - ------------------------------------------------------------------------------ 3 SEC USE ONLY - ------------------------------------------------------------------------------ - ------------------------------------------------------------------------------ 4 CITIZENSHIP OR PLACE OF ORGANIZATION United States of America - ------------------------------------------------------------------------------ - ------------------------------------------------------------------------------ 5 SOLE VOTING POWER 0 NUMBER OF --------------------------------------------------------------- --------------------------------------------------------------- --------------------------------------------------------------- SHARES 6 SHARED VOTING POWER BENEFICIALLY OWNED BY 8,749,996 --------------------------------------------------------------- --------------------------------------------------------------- EACH 7 SOLE DISPOSITIVE POWER REPORTING PERSON 0 --------------------------------------------------------------- --------------------------------------------------------------- WITH 8 SHARED DISPOSITIVE POWER 8,749,996 - ------------------------------------------------------------------------------ - ------------------------------------------------------------------------------ 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9,128,376 - ------------------------------------------------------------------------------ - ------------------------------------------------------------------------------ 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* [ ] - ------------------------------------------------------------------------------ - ------------------------------------------------------------------------------ 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 6.9% - ------------------------------------------------------------------------------ - ------------------------------------------------------------------------------ 12 TYPE OF REPORTING PERSON* IA - ------------------------------------------------------------------------------ - ------------------------------------------------------------------------------ 1 NAME OF REPORTING PERSONS S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) LCS, LLC - ------------------------------------------------------------------------------ - ------------------------------------------------------------------------------ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [ ] - ------------------------------------------------------------------------------ - ------------------------------------------------------------------------------ 3 SEC USE ONLY - ------------------------------------------------------------------------------ - ------------------------------------------------------------------------------ 4 CITIZENSHIP OR PLACE OF ORGANIZATION A Delaware Limited Liability Corporation - ------------------------------------------------------------------------------ - ------------------------------------------------------------------------------ 5 SOLE VOTING POWER 0 NUMBER OF --------------------------------------------------------------- --------------------------------------------------------------- SHARES 6 SHARED VOTING POWER BENEFICIALLY OWNED BY 547,200 --------------------------------------------------------------- --------------------------------------------------------------- EACH 7 SOLE DISPOSITIVE POWER REPORTING PERSON 0 --------------------------------------------------------------- --------------------------------------------------------------- WITH 8 SHARED DISPOSITIVE POWER 547,200 - ------------------------------------------------------------------------------ - ------------------------------------------------------------------------------ 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 547,200 - ------------------------------------------------------------------------------ - ------------------------------------------------------------------------------ 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* [ ] - ------------------------------------------------------------------------------ - ------------------------------------------------------------------------------ 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) Less than 1% - ------------------------------------------------------------------------------ - ------------------------------------------------------------------------------ 12 TYPE OF REPORTING PERSON* CO - ------------------------------------------------------------------------------ - ------------------------------------------------------------------------------ 1 NAME OF REPORTING PERSONS S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) John A. Levin - ------------------------------------------------------------------------------ - ------------------------------------------------------------------------------ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [ ] - ------------------------------------------------------------------------------ - ------------------------------------------------------------------------------ 3 SEC USE ONLY - ------------------------------------------------------------------------------ - ------------------------------------------------------------------------------ 4 CITIZENSHIP OR PLACE OF ORGANIZATION United States of America - ------------------------------------------------------------------------------ - ------------------------------------------------------------------------------ 5 SOLE VOTING POWER 0 NUMBER OF --------------------------------------------------------------- --------------------------------------------------------------- --------------------------------------------------------------- SHARES 6 SHARED VOTING POWER BENEFICIALLY OWNED BY 1,803,810 --------------------------------------------------------------- --------------------------------------------------------------- EACH 7 SOLE DISPOSITIVE POWER REPORTING PERSON 0 --------------------------------------------------------------- --------------------------------------------------------------- WITH 8 SHARED DISPOSITIVE POWER 1,803,810 - ------------------------------------------------------------------------------ - ------------------------------------------------------------------------------ 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9,128,376 - ------------------------------------------------------------------------------ - ------------------------------------------------------------------------------ 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* [ ] - ------------------------------------------------------------------------------ - ------------------------------------------------------------------------------ 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 6.9% - ------------------------------------------------------------------------------ - ------------------------------------------------------------------------------ 12 TYPE OF REPORTING PERSON* IN - ------------------------------------------------------------------------------ ITEM 1. (A) NAME OF ISSUER: Gamida Cell Ltd. (the "Issuer"). (B) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES OR, IF NONE, RESIDENCE: 116 Huntington Avenue, 7th Floor, Boston, MA 02116. ITEM 2. (A) NAME OF PERSON FILING: This schedule is being jointly filed by Levin Capital Strategies, L.P. ("LCS"), Levin Capital Strategies GP, LLC ("LCSGP"), LCS, LLC ("LCSL"), and John A. Levin, the Chief Executive Officer and controlling person of LCS, LCSGP, LCSL, (LCS, LCSGP, LCSL, and John A. Levin are sometimes collectively referred to hereinafter as "Filer"). Attached hereto as an exhibit is a copy of the joint Schedule 13G filing agreement among the reporting persons and entities. (B) ADDRESS OF PRINCIPAL BUSINESS OFFICE: The address of the principal executive office of LCS, LCSGP, LCSL, and John A. Levin is: 767 Fifth Avenue, 18th Floor, New York, New York 10153. (C) CITIZENSHIP: The citizenship or place of organization of the reporting person is as follows: LCS is a limited partnership organized under the laws of the State of Delaware, and LCSGP, LCSL are limited liability corporations organized under the laws of the State of Delaware. John A. Levin is a citizen of the United States of America. (D) TITLE OF CLASS OF SECURITIES: Ordinary shares, par value NIS 0.01 per share (the "Ordinary Shares") (E) CUSIP NUMBER: M47364100 ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO 13d-1(B), OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A: IF THIS STATEMENT IS FILED PURSUANT TO 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A: (a) [ ] Broker or dealer registered under Section 15 of the Act (b) [ ] Bank as defined in Section 3(a)(6) of the Act (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (e) [x] Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940: see Rule 13d-1(b)(1)(ii)(E) (f) [ ] Employee Benefit Plan, Pension Fund which is subject to the provisions of the Employee Retirement Income Security Act of 1974 or Endowment Fund; see Rule 13d-1(b)(1)(ii)(F) (g) [ ] Parent Holding Company, in accordance with Rule 13d- 1(b)(ii)(G); (h) [ ] Savings Associations as defined in Section 3(b) of the Federal Deposit Insurance Act; (i) [ ] Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940; (j) ( ) Group, in accordance with Rule 13d-1(b)(1)(ii)(J). IF THIS STATEMENT IS FILED PURSUANT TO Rule 13d-1(c), CHECK THIS BOX.[] ITEM 4. OWNERSHIP. Levin Capital Strategies, L.P.: (a) Amount beneficially owned: 9,128,376 (b) Percent of Class: Less than 6.9% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 8,749,996 (iii) Sole power to dispose or to direct the disposition of: 0 (iv) Shared power to dispose of to direct the disposition of: 8,749,996 Levin Capital Strategies GP, LLC: (a) Amount beneficially owned: 9,128,376 (b) Percent of Class: Less than 6.9% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 8,749,996 (iii) Sole power to dispose or to direct the disposition of: 0 (iv) Shared power to dispose of to direct the disposition of: 8,749,996 LCS, LLC: (a) Amount beneficially owned: 547,200 (b) Percent of Class: Less than Less than 1.0% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Share power to vote or to direct the vote: 547,200 (iii) Sole power to dispose or to direct the disposition of: 0 (iv) Shared power to dispose of to direct the disposition of: 547,200 Mr. Levin disclaims beneficial ownership of all such shares. John A. Levin: (a) Amount beneficially owned: 9,128,376 (b) Percent of Class: Less than 6.9% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Share power to vote or to direct the vote: 1,803,810 (iii) Sole power to dispose or to direct the disposition of: 0 (iv) Shared power to dispose of to direct the disposition of: 1,803,810 ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following []. ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON. This Schedule 13G is filed by LCS, LCSGP, and LCSL and John A. Levin with respect to Common Stock held by LCS's investment advisory accounts. Bi-Directional Disequilibrium Fund, L.P, a private fund for which LCS acts as investment advisor, has the right to receive dividends from, and the proceeds from the sale of 547,200 shares. Various separately managed accounts for whom LCS acts as investment manager have the right to receive dividends from, and the proceeds from the sale of, 8,581,176 shares. ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY. Not Applicable. ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP. Not applicable. ITEM 9. NOTICE OF DISSOLUTION OF GROUP. Not applicable. ITEM 10. CERTIFICATION. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purposes or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 8, 2024 --------------------------- (Date) LEVIN CAPITAL STRATEGIES, L.P. By:/s/ JOHN A. LEVIN -------------------------- John A. Levin Chairman and Chief Executive Officer Levin Capital Strategies GP, LLC By: John A. Levin 2005 GRAT Separation Trust, as Managing Member By: /s/ ELISABETH LEVIN ----------------------------- Elisabeth Levin, Trustee LCS, LLC BY:/s/ JOHN A. LEVIN ------------------------ John A. Levin General Partner By:/s/ JOHN A. LEVIN ------------------------- John A. Levin

Get the next $GMDA alert in real time by email

Date	Price Target	Rating	Analyst
11/16/2021	$14.00 → $12.00	Buy	Needham
11/16/2021	$17.00 → $15.00	Outperform	Oppenheimer
11/1/2021	$11.00	Buy	Alliance Global Partners

SEC Form SC 13G filed by Gamida Cell Ltd.

Chat with this insight

Recent Analyst Ratings for $GMDA

$GMDA Press Releases

Fastest customizable press release news feed in the world

HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200

XORTX Welcomes New Member to the Board of Directors

Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive

$GMDA Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Needham reiterated coverage on Gamida Cell with a new price target

Oppenheimer reiterated coverage on Gamida Cell with a new price target

Alliance Global Partners initiated coverage on Gamida Cell with a new price target

$GMDA SEC Filings

SEC Form EFFECT filed by Gamida Cell Ltd.

SEC Form EFFECT filed by Gamida Cell Ltd.

SEC Form EFFECT filed by Gamida Cell Ltd.

$GMDA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Moch Kenneth I was granted 200,000 units of Ordinary Shares, increasing direct ownership by 619% to 232,300 units (SEC Form 4)

Wills Stephen T was granted 200,000 units of Ordinary Shares, increasing direct ownership by 356% to 256,177 units (SEC Form 4)

Tomasello Shawn was granted 200,000 units of Ordinary Shares, increasing direct ownership by 476% to 241,977 units (SEC Form 4)

$GMDA Leadership Updates

Live Leadership Updates

HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200

XORTX Welcomes New Member to the Board of Directors

Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive

$GMDA Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Gamida Cell Ltd. (Amendment)

SEC Form SC 13G/A filed by Gamida Cell Ltd. (Amendment)

SEC Form SC 13G/A filed by Gamida Cell Ltd. (Amendment)

$GMDA FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

$GMDA Financials

Live finance-specific insights

April 17, 2023 - FDA Approves Cell Therapy for Patients with Blood Cancers to Reduce Risk of Infection Following Stem Cell Transplantation

Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results

Gamida Cell to Report Third Quarter 2023 Financial Results

Gamida Cell to Report Second Quarter 2023 Financial Results

$GMDA Market Insights

Live Market Insights

Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Why Cal-Maine Foods Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Recent Analyst Ratings for
$GMDA

$GMDA
Press Releases

$GMDA
Analyst Ratings

$GMDA
SEC Filings

$GMDA
Insider Trading

$GMDA
Leadership Updates

$GMDA
Large Ownership Changes

$GMDA
FDA approvals

$GMDA
Financials

$GMDA
Market Insights